Abstract
While there has been a series of real-world studies on ALK-positive non-small cell lung cancer (NSCLC) in the advanced/metastatic setting, there are far fewer reports about the outcome of early stage ALK-positive cancer. The aim of this analysis was to study treatment patterns and outcomes in a real-world cohort of patients with ALK+ NSCLC diagnosed in stages I-III.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
